AIM ImmunoTech, Inc. (AIM)
| Market Cap | 94.71M |
| Revenue (ttm) | 146,000 |
| Net Income (ttm) | -14.19M |
| Shares Out | 45.73M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $2.00 |
| Previous Close | $1.98 |
| Change ($) | 0.02 |
| Change (%) | 1.01% |
| Day's Open | 1.98 |
| Day's Range | 1.97 - 2.01 |
| Day's Volume | 250,802 |
| 52-Week Range | 1.60 - 3.16 |
Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen's effectiveness against those, and potential...
OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 202...
Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis
The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for U...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential inha...
Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive Announces plans to conduct Phase 1/2 clinical study inc...
OCALA, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerabi...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Thomas Equels told investors that the immuno-pharma company rounded out the first quarter by increasing its cash reserves to “aggressively move forward” with it...
OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.
OCALA, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat' video interview with Ed W...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) said it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as an intranasal therap...
OCALA, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolera...
AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID-19 and other resp...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no serious a...
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug ...
Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of co...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that it ended 2020 with cash, cash equivalents, and marketable securities of $54.4 million. That's a sizable increase compared to the $8.8 mill...
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) has announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center has approved a protocol amendment to Roswell Park's ongoing Phas...
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Pa...
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM's Chief Executive Officer, has been invited to present at the Inaugura...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Monday that it has dosed the first healthy subjects in its Phase 1 clinical study of Ampligen as a potential intranasal therapy for the coronavirus (CVOID...
Marks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases Marks important milestone towards development of Ampli...
OCALA, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. ...
AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as a trea...
Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of co...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that its subsidiary NV Hemispherx Biopharma Europe has received formal notification from the European Commission approving the company's Orphan ...
OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the Eur...
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) said it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of its drug Ampligen as an...
OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence it...
AIM ImmunoTech Inc (NYSE: AIM) shares are rising today after the company announced that the Netherlands regulatory authority had approved treatment for six pancreatic cancer patients as part of a new, f...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that the Dutch Health and Youth Care Inspectorate (IGJ) has approved use of its treatment for six pancreatic cancer patients as part of a new, f...
Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access Program Early Access Program Will Also Allow Further Treatment of Patients Treated Und...
AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) said it has completed its At-The-Market (ATM) facility and close the ATM's Equity Distribution Agreement (EDA). The company, which focuses on developing...
OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM's Equity Distribution Ag...
AIM is Working to Develop an Effective COVID-19 Intranasal Therapy AIM is Working to Develop an Effective COVID-19 Intranasal Therapy
AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fat...
OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week's planned investor conference call will be postponed a...
AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones AIM to host investor...
Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for Potential ...
OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral...
AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and C...
OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the dise...
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral...
Early Onset Therapy May Be Key to COVID Long Hauler Syndrome Early Onset Therapy May Be Key to COVID Long Hauler Syndrome
TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines Ent...
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis,... [Read more...]
| Industry Biotechnology | Founded 1966 |
| CEO Thomas Equels | Employees 21 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol AIM |
Financial Performance
In 2020, AIM ImmunoTech's revenue was $163,000, an increase of 16.43% compared to the previous year's $140,000. Losses were -$14.40 million, 53.1% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for AIM ImmunoTech stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 225.00% from the latest price.